TY - JOUR
T1 - Long‐term results in the treatment of acute nonlymphocytic leukemia
T2 - A pediatric oncology group study
AU - Krischer, Jeffrey P.
AU - Steuber, C. Philip
AU - Vietti, Teresa J.
AU - Culbert, Steven J.
AU - Ragab, Abdelsalam H.
AU - Morgan, Samuel K.
AU - Berry, D. H.
AU - Hvizdala, Eva
AU - Thomas, Paul J.
AU - Land, Vita J.
AU - Castleberry, Robert P.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - Complete remission (CR), 5‐year remission duration (RD), and overall 5‐year survival rates are 74%, 28%, and 25%, respectively, for previously untreated children with acute nonlymphocytic leukemia diagnosed between 1977 and 1981, following induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6‐thioguanine, cytosine arabinoside (TA) and cyclophosphamide/vincristine/cytosine arabinoside/prednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses. Approximately 20% are free of their disease for more than 5 years. High white blood cell counts (WBC) at diagnosis and M3 and M6 morphology were associated with lower CR rates, while M5 morphology was associated with higher CR rates. Patients with M1 morphology had shorter remission duration as compared to those with M4 or M5 morphology. Low WBC and age between 2 and 10 years at diagnosis were associated with longer remission durations and survival. Patients with M4 morphology also survived longer. The observed CR rates are comparable to other studies initiated at the same time as this study but survival is less than those reported more recently. Low WBC at diagnosis and M4/M5 morphology may identify relatively favorable prognostic groups.
AB - Complete remission (CR), 5‐year remission duration (RD), and overall 5‐year survival rates are 74%, 28%, and 25%, respectively, for previously untreated children with acute nonlymphocytic leukemia diagnosed between 1977 and 1981, following induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6‐thioguanine, cytosine arabinoside (TA) and cyclophosphamide/vincristine/cytosine arabinoside/prednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses. Approximately 20% are free of their disease for more than 5 years. High white blood cell counts (WBC) at diagnosis and M3 and M6 morphology were associated with lower CR rates, while M5 morphology was associated with higher CR rates. Patients with M1 morphology had shorter remission duration as compared to those with M4 or M5 morphology. Low WBC and age between 2 and 10 years at diagnosis were associated with longer remission durations and survival. Patients with M4 morphology also survived longer. The observed CR rates are comparable to other studies initiated at the same time as this study but survival is less than those reported more recently. Low WBC at diagnosis and M4/M5 morphology may identify relatively favorable prognostic groups.
KW - ANLL
KW - prognostic factors
KW - remission rates
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=0024448438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024448438&partnerID=8YFLogxK
U2 - 10.1002/mpo.2950170509
DO - 10.1002/mpo.2950170509
M3 - Article
C2 - 2796855
AN - SCOPUS:0024448438
VL - 17
SP - 401
EP - 408
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 5-6
ER -